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Screening of a panel of steroid-related genes showed polymorphisms of
aromatase genes confer susceptibility to advanced stage endometriosis in
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Accepted 15 May 2012AbstractObjective: To establish a multilocus model for studying the effect of steroid-related genes on advanced stage endometriosis.
Materials and methods: A total of 121 patients with advanced stage endometriosis and 171 control women were included. Eighteen single-
nucleotide polymorphisms (SNPs) from nine genes (HSD17B1, HSD17B2, HSD17B5, HSD17B6, CYP17, CYP19, ERa, ERb, and PGR)
were genotyped using the TaqMan assays. Logistic regression models were used to evaluate the genetic effects, with adjustment for other
covariates.
Results: Only the presence of the mutant CYP19 (aromatase gene) was associated with a significantly increased risk of endometriosis after
adjusting for age, BMI, and parity ( p ¼ 0.002, OR ¼ 2.69; 95% CI ¼ 1.44e5.02). No association was ascertained between the other investigated
SNPs and endometriosis.
Conclusion: Polymorphisms of the aromatase gene confer susceptibility to advanced stage endometriosis in the Taiwanese Han population.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Endometriosis, the presence of endometrium-like tissue in
sites outside the uterine cavity, is an estrogen-dependent in-
flammatory disease that affects 6e10% of women of repro-
ductive age in the United States [1]. Their common histologic
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http://dx.doi.org/10.1016/j.tjog.2013.10.006cells, chronic bleeding, and signs of inflammation. These le-
sions can occur singly or in combination and are associated
with an increased risk of infertility or chronic pelvic pain
[2,3].
Endometriosis develops mostly in women of reproductive
age and regresses after the menopause or ovariectomy, and the
lesion relapses in postmenopausal women under estrogen
replacement therapy, suggesting that the growth of endome-
triosis is estrogen-dependent [4]. Clinical evidence clearly
points to a deleterious effect of uninterrupted ovulatory cycles
on the development and persistence of endometriosis [5]. An
increase in the local concentration of estrogen resulting from
the absence of 17b-hydroxysteroid dehydrogenase (HSD17B)
type 2 in pelvic endometriotic implants was found [6]. Nocs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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was detectable in disease-free uterine endometrium, but there
were increased StAR and aromatase levels in extra-ovarian
endometriotic implants and endometriomas [7e10]. These
studies and the presence of estrogen receptors (ER) and aro-
matase in endometriosis lesions indicate that local estrogen
production may stimulate the growth of lesions [11]. Biolog-
ically significant quantities of progesterone and estrogen are
produced locally in endometriotic tissue through an abnor-
mally active aromatase and steroidogenic cascade [11]. In
studies on humans and other primates, estrogen stimulates the
growth of endometriotic tissue, whereas aromatase inhibitors
that block estrogen formation are beneficial in patients with
endometriosis [12e14].
Endometriosis is evolving from a local disorder to a com-
plex, chronic systemic disease, as its underlying cellular and
molecular mechanisms are being uncovered [15]. Endometri-
osis can be inherited in a polygenic manner given that its
incidence in relatives of affected women is up to seven times
the incidence in women without such a family history [16],
and with a five- to eightfold increase in the risk of occurrence
in first-degree relatives [17]. Numerous studies have attempted
to identify susceptible alleles for endometriosis [18e20].
Some genetic studies have revealed an association between the
development of endometriosis and the polymorphisms of
several genes, including the genes related to estrogen meta-
bolism [4, 21]. The PvuII polymorphism of the ERa gene is
associated with the risk of endometriosis [22,23]. ERa14
thymine-adenine repeats polymorphism and the cytochrome
P450, family 17, subfamily A, polypeptide 1 (CYP17 A1)
allele polymorphism were shown to be associated with an
increased risk of endometriosis in Taiwanese women [24]. It
was also found that ER-351 XbaI*G- and -397 PvuII*C-
related genotypes alleles were correlated with higher suscep-
tibilities of endometriosis [25]. The 3 bp I/D polymorphism of
the CYP19 A1 gene was shown to be weakly associated with
susceptibility to endometriosis [21]. The A-allele of
HSD17B1, the Ser312Gly polymorphism, appeared to confer a
higher risk of endometriosis in Japanese women [26].
Although efforts have been devoted to explore the role of ER
complex components and aromatase enzymes in endometri-
osis, these studies usually focused on a single gene or just
several genes. Moreover, results of these studies were quite
often not consistent [18e20].
In this study, we aimed to investigate the association be-
tween endometriosis and a more complete panel of multiple
gene polymorphisms in estrogen synthesis and estrogen targets
in the Taiwanese Han population. Eighteen genetic variants
from nine genes (HSD17B1, HSD17B2, HSD17B5, HSD17B6,
CYP17, CYP19, ERa, ERb, and PGR) were genotyped. The
above listed single-nucleotide polymorphisms (SNPs) were
selected because the respective gene products are involved in
estrogen metabolism or targets, and can thus be seen as
candidate genes for endometriosis. For example, variant
CYP17, and CYP19 enzymes have been noted to be associated
with significant changes in serum hormone concentrations
[14]. Variations of the ERa gene lead to significant alterationsin the response to therapy with estrogen [12]. HSD17B cata-
lyzes the final step of estradiol (E2) biosynthesis. Type 1 and 7
HSD17B catalyzes the transformation of estrone (E1) into E2
[27]. We thus attempted to establish a multiple genetic model
based on geneegene interactions to define potentially critical
SNP combinations in the susceptibility to endometriosis.
Materials and methodsParticipantsThe study was approved by the institutional review board of
Changhua Christian Hospital (CCH060708) and informed
written consent was obtained from each woman. The partici-
pants of the study are the same as in the previous study [28].
From September 2006 and December 2009, we recruited 121
infertile women who had pathologic confirmation of stage III⁄
IV (advanced stage) endometriosis and underwent laparotomy
or laparoscopy. The extent of the disease was staged according
to the guidelines of the American Society for Reproductive
Medicine [29]. This is a case-control study where we enrolled
171 women as controls who had delivered at least one full-
term healthy baby without the aid of assisted reproductive
technologies and had not experienced miscarriage or preg-
nancy complications. Women with the following conditions
were excluded: infertility, dysmenorrhea, hypermenorrhea,
irregular menstruation, surgical history of any gynecologic
diseases, or previous diagnosis of endometriosis and adeno-
myosis. All individuals belonged to the Taiwanese Han, the
major ethnic group in Taiwan (making up >95% of the
country’s population). All patients underwent a comprehensive
examination, including a detailed history, physical examina-
tion, and hormone assays.GenotypingPeripheral venous blood samples were obtained from par-
ticipants. Genomic DNA was extracted from lymphocytes
using a Puregene DNA isolation kit (Gentra, Minneapolis,
MN, USA). We searched polymorphisms, which are available
online at http://www.ncbi.nlm.nih.gov/SNP/ or http://www.
ensembl.org, for estrogen synthesizing/transporting genes
(HSD17B1, HSD17B2, HSD17B5, HSD17B6, CYP17,
CYP19), ER genes (ERa, ERb), and progesterone receptor
gene (PGR). SNPs of these genes had been reported to be
associated with at least two of the following steroid hormone-
related disorders: breast cancer, endometrial cancer, prostate
cancer, endometriosis, precocious puberty, and polycystic
ovarian syndrome in peer-review articles (http://www.ncbi.
nlm.nih.gov/sites/entrez?db¼PubMed). A total of 18 SNPs
were chosen out of nine genes. These SNPs were detected by
primer extension analysis using endpoint TaqMan assays
(Applied Biosystems, Warrington, UK) in 96-well arrays, and
genotypes were subsequently read on a 7900 Sequence De-
tector (Applied Biosystems). The detailed protocol of SNP
typing is available on request to the corresponding investi-
gator. The control samples for TaqMan assay had been
Table 1
Demographic distribution among participants.
Age (y) BMI (kg/m2) Parity
Endometriosis (n ¼ 121) 30.9  6.3* 22.1  3.6 0.7  1.1**
Control (n ¼ 171) 29.1  4.3 22.7  1.3 1.7  0.6
*p ¼ 0.004.
**p < 0.001 compared with controls.
BMI ¼ body mass index.
487C.-H. Wu et al. / Taiwanese Journal of Obstetrics & Gynecology 52 (2013) 485e492confirmed by direct genomic DNA sequence analysis per-
formed using an automatic sequencer (Applied Biosystems).Statistical analysisLogistic regression models were used to evaluate the ge-
netic effect, with adjustment for other covariates. Any variant
with a p value <0.05 was considered significant. Throughout
statistical analysis, SNPs were considered binary variables
using a dominant gene model, i.e., homozygous wild-type
compared with heterozygous and homozygous mutant (wild-
type to wild-type, compared with wild-type to mutant and
mutant to mutant). The association of SNPs with the presence
of endometriosis was evaluated and expressed as odds ratios
(OR) and 95% confidence intervals (CI).Results
The study included a total of 121 patients with advanced
stage endometriosis and 171 control women (Table 1). The
mean age was 30.9  6.3 versus 29.1  4.3 years for endo-
metriosis patients and controls, respectively. The BMI and
parity were 22.1  3.6 versus 22.7  1.3 kg/m2 and 0.7  1.1
versus 1.7  0.6 for endometriosis patients and controls,
respectively. There were significant differences between pa-
tients with endometriosis and control participants in age andTable 2
Distribution of CYP gene polymorphisms among endometriosis patients and contr
Genotype SNP ID Patients, n (%)
CYP17 rs743572
Genotype frequency
AGa 52 (43.0)
AA þ GG 69 (57.0)
CYP17 rs10786712
Genotype frequency
CTa 50 (41.3)
CC þ TT 71 (59.7)
CYP19 rs10046
Genotype frequency
AGa 60 (49.6)
AA þ GG 61 (50.4)
CYP19 rs8042086
Genotype frequency
TTa 30 (24.8)
CT þ CC 91 (75.2)
CI ¼ confidence interval; CYP ¼ cytochrome P450; OR ¼ odds ratio; SNP ¼ sing
parity.
a Denotes the reference group for pairwise comparisons.parity; therefore, they were adjusted in the multivariable lo-
gistic regression models for analyses. The genotype distribu-
tions of each SNP were in HardyeWeinberg equilibrium for
both endometriosis patients and controls.
Only the presence of the mutant rs8042086 CYP19 (aro-
matase gene) was associated with a significantly increased risk
of endometriosis after adjusting for age, BMI, and parity. The
C⁄T þ C⁄C genotypes of CYP19 showed a statistically signif-
icant association with endometriosis compared with to the T⁄T
genotype ( p ¼ 0.002, OR ¼ 2.69; 95% CI ¼ 1.44e5.02)
(Table 2). No association was ascertained between the other
investigated SNPs and the presence or absence of endometri-
osis (Tables 3 and 4).
Discussion
Implementation of genetic testing has been applied to
clinical practice in medical subspecialties such as hematology
and clinical pharmacology [30]. Candidate genes are gener-
ally chosen based on biological mechanisms relevant to the
disease. Genetic variants in these candidate genes are geno-
typed in samples from cases and controls, or in affected
families to test for association by statistical analysis. For
endometriosis, candidates tested include genes from detoxi-
fication pathways, sex steroid pathways, cytokine signaling
pathways, adhesion molecules and matrix enzymes, and cell-
cycle regulators [18]. In the past decade, a considerable
number of genetic studies have been carried out to explore the
association of various pathways with endometriosis, such as
catechol-O-methyltransferase (COMT) [31], intron G of the
progesterone receptor [32], ER [23,24,33,34], IL-6 [35],
vascular endothelial growth factor [36], HSD17B1,
HSD17B2, and HSD17B7 [37], CYP17 and CYP19 [21,38],
and AhRR [39]. Many of these studies have been reviewed
recently in detail for association with endometriosis suscep-
tibility [18,19,40e42]. Most of the studies investigated only aols.
Controls, n (%) p OR (95% CI)
89 (52.0)
82 (48.0) 0.366 1.31 (0.73e2.34)
88 (51.4)
83 (48.6) 0.322 1.34 (0.75e2.40)
87 (50.9)
84 (49.1) 0.874 0.95 (0.54e1.70)
84 (49.1)
87 (50.9) 0.002 2.69 (1.44e5.02)
le-nucleotide polymorphisms. Results adjusted for age, body mass index, and
Table 3
Distribution of HSDs gene polymorphisms among endometriosis patients and controls.
Genotype SNP ID Patients, n (%) Controls, n (%) p OR (95% CI)
HSD17B1 rs605059
Genotype frequency
AGa 61 (50.4) 87 (50.9)
AA þ GG 60 (49.6) 84 (49.1) 0.441 1.27 (0.69e2.32)
HSD17B1 rs676387
Genotype frequency
ACa 57 (47.1) 85 (49.7)
AA þ CC 64 (52.9) 86 (50.3) 0.272 1.40 (0.77e2.53)
HSD17B2 rs8191246
Genotype frequency
AAa 115 (95.0) 157 (91.8)
AG þ GG 6 (5.0) 14 (8.2) 0.491 1.40 (0.20e2.18)
HSD17B2 rs11642323
Genotype frequency
CTa 59 (48.8) 85 (49.7)
CC þ TT 62 (51.2) 86 (50.3) 0.572 1.40 (0.47e1.51)
HSD17B2 rs8191138
Genotype frequency
GGa 59 (48.8) 89 (52.0)
AG þ AA 62 (51.2) 82 (48.0) 0.425 1.27 (0.71e2.28)
HSD17B5 rs12529
Genotype frequency
GGa 88 (72.7) 127 (74.3)
CG þ CC 33 (27.3) 44 (25.7) 0.820 1.08 (0.55e2.11)
HSD17B6 rs898611
Genotype frequency
TTa 64 (52.9) 96 (56.1)
CT þ CC 57 (47.1) 75 (43.9) 0.289 1.38 (0.76e2.52)
HSD17B6 rs7967600
Genotype frequency
GGa 64 (52.9) 96 (56.1)
AG þ AA 57 (47.1) 75 (43.9) 0.332 1.34 (0.74e2.40)
CI ¼ confidence interval; HSD ¼ hydroxysteroid dehydrogenase; OR ¼ odds ratio; SNP ¼ single-nucleotide polymorphisms. Results adjusted for age, body mass
index, and parity.
a Denotes the reference group for pairwise comparisons.
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correction of multiple comparisons could not be obtained.
Thus far, only a few additive effects of multiple SNPs have
been described [28,30]. Identifying critical combinations of
SNPs conferring additive risks of developing endometriosis
would be of clinical interest for defining high-risk pop-
ulations, or for identifying women most likely to benefit from
pharmacologic interventions related to the gene product of
the respective SNPs, e.g., antiestrogens [30]. We thus set out
to investigate a combination of multiple SNPs (HSD17B1,
HSD17B2, HSD17B5, HSD17B6, CYP17, CYP19, ERa, ERb,
and PGR) involved in estrogen metabolism simultaneously.
This study demonstrates that the presence of the mutant
rs8042086 of CYP19 (aromatase gene) is associated with a
significant risk of developing advanced endometriosis. Except
for HSD17B2, HSD17B5, and HSD17B6, most SNPs chosen
for genotyping in this study have been shown to be signifi-
cantly associated with endometriosis or other estrogen-related
diseases. However, the correlation could not be replicated in
our samples.
The net production of 17b-E2 is the result of a delicate
balance between the synthesis and the inactivation of E2 [43].
Enzymes encoded by the HSD17B family catalyze theinterconversion between higher activity 17b-hydroxysteroids
and lower activity 17-ketosteroids, and thus regulate the bio-
logical activity of sex steroids, including estrogen. In humans,
aromatase produces mainly E1 and some HSD17Bs play the
role for the synthesis of E2 from E1. The production of E2 is
mediated through the HSD17B type 1, 3, 5, 7, and 12, as well as
steroid sulfatase (STS), which converts the sulfated estrogens to
biologically active estrogens [44e46]. Gene transcripts for
types 1 and 7 HSD17B and estrogen sulfatase were found to be
overexpressed in endometriotic tissues when compared with
normal endometrium [43]. The conversion of E2 into less active
metabolites in endometrium tissue is based on enzymatic ac-
tions of HSD17Bs types 2, 4, and 8, which form by an oxidative
reaction to androstenedione and E1 [47]. The type 2 HSD17B is
believed to be one of the most important E2-inactivating en-
zymes in the endometrium [48]. The general consensus is that
the expression of type 2 HSD17B is reduced or absent in eutopic
and ectopic endometrium of endometriosis patients [43,49].
The expression pattern of aromatase and the regulation of
17bHSD-2 were found to be altered in the eutopic endometrium
of women with endometriosis compared to that of women
without disease [4]. Inactivation of 17b-E2 is impaired in
endometriotic tissues due to deficient expression of 17bHSD-2,
Table 4
Distribution of estrogen and progesterone receptor gene polymorphisms among endometriosis patients and controls.
Genotype SNP ID Patients, n (%) Controls, n (%) p OR (95% CI)
ERa rs1801132
Genotype frequency
CGa 65 (53.7) 80 (46.8)
CC þ GG 56 (46.3) 91 (53.2) 0.524 0.83 (0.46e1.48)
ERa rs2077647
Genotype frequency
CTa 48 (39.7) 77 (45.1)
CC þ TT 73 (60.3) 94 (54.9) 0.841 1.06 (0.59e1.93)
ERa rs2228480
Genotype frequency
GGa 67 (55.4) 111 (64.9)
AG þ AA 54 (44.6) 60 (35.1) 0.133 1.59 (0.87e2.92)
ERb rs4986938
Genotype frequency
CCa 97 (80.2) 140 (81.9)
CT þ TT 24 (19.8) 31 (18.1) 0.369 1.41 (0.67e2.99)
ERb rs1256049
Genotype frequency
CTa 61 (50.4) 82 (48.0)
CC þ TT 60 (49.6) 89 (52.0) 0.810 1.07 (0.60e1.92)
PGR rs1042838
Genotype frequency
CCa 116 (95.9) 167 (97.7)
AC þ AA 5 (4.1) 4 (2.3) 0.491 1.40 (0.20e2.18)
CI ¼ confidence interval; ER ¼ estrogen receptor; OR ¼ odds ratio; PGR ¼ progesterone receptor; SNP ¼ single-nucleotide polymorphisms. Results adjusted for
age, body mass index, and parity.
a Denotes the reference group for pairwise comparisons.
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response to progesterone [6].
The haplotypes of the HSD17B1 gene have been associated
with elevated E2 levels and breast cancer, an estrogen-
dependent disease [50]. It has been suggested that the pres-
ence of SNP vlV A->C of HSD17B1 promotes the develop-
ment of endometriosis [30]. The transcripts of the reductive
HSD17B type 1, which catalyzes the conversion of E1 to E2,
are expressed in both eutopic endometrium and endometriosis.
In contrast, HSD17B type 2 messenger ribonucleic acids are
present in all samples of secretory eutopic endometrium, but
not in secretory samples of endometriotic lesions [6]. Evi-
dence for association between the Ser312Gly polymorphism in
HSD17B1 and endometriosis was found in a Japanese popu-
lation. The A-allele of HSD17B1 appears to confer higher risk
for endometriosis in Japanese women [26]. The study also
provided evidence of HSD17B1 vlV A->C as a low pene-
trance genetic marker of endometriosis in a population of
middle-European origin [30]. Besides HSD17B1 and
HSD17B2, other members of the HSD17B family in relation to
the risk of endometriosis have not been explored. We have
thus investigated a more comprehensive panel of HSD17B
genes. For the first time, an attempt was made to explore the
association of HSD17B5, and HSD17B6 genes in endometri-
osis. We did not identify a positive association in all SNPs
tested. For the progesterone receptor gene, rs1042838 was in
complete linkage disequilibrium with the most representative
functional SNP (PROGIN) in the Taiwanese. In addition,
rs1042838-PROGIN was significantly associated withrecurrent pregnancy loss in our population [51]. Although only
two to four SNPs were genotyped for each of the remaining
genes, these SNPs have been shown to be associated with
steroid hormone-related diseases in our previous publications
[51,52].
Aromatase overexpression has been confirmed in numerous
reports on endometriosis in terms of the transcript level
[7,37,53], protein level [8,9,54,55], as well as the enzymatic
activity level [8,54]. The CYP17 gene mediates both steroid
17a-hydroxylase and 17,20-lyase activities and plays a key
role in androgen biosynthesis. The CYP19A1 gene codes for
aromatase enzymes involved in conversion of androgen to
estrogen. Previous studies on Taiwanese women have shown a
possible relation between endometriosis susceptibility and the
234T/C polymorphism in the promoter region of the CYP17A1
gene [24,56]. However, no strong association with CYP17A1
polymorphisms has been found in other studies of UK, Bra-
zilian, Austrian, Taiwanese, or Japanese populations
[21,30,57e59]. Although of similar ethnic background, we
also could not prove the association between the CYP17A1
SNP and endometriosis. The TTTA repeat microsatellite in the
CYP19A1 gene showed no association in Japanese women
with endometriosis [21] and the risk of endometriosis was
increased in Greek women [60]. Another polymorphism in this
gene (CYP19 Arg264Cys C->T) was studied in Japanese and
Austrian women, but did not appear to influence endometriosis
susceptibility [26,30]. The 3 bp I/D polymorphism of the
CYP19A1 gene was shown to be only weakly associated with
the susceptibility to endometriosis [21]. The polymorphisms
490 C.-H. Wu et al. / Taiwanese Journal of Obstetrics & Gynecology 52 (2013) 485e492C1558T (rs700519) of CYP19 were related to endometriosis in
an Italian population [38]. In this study, we demonstrated that
the polymorphism of the CYP19 SNP (rs8042086) was asso-
ciated with susceptibility to endometriosis.
A review of association studies for CYP17A1, CYP19A1,
androgen receptor (AR), PGR and ERa, ERb concluded that
many reported positive findings were unsound because of
problems with data analysis in the original reports [42].
Almost all previous published studies were limited by the
small sample size, only single SNP in each gene, and many
results were controversial in different studies and/or different
population groups [19,20]. Thus, population difference may be
an important factor in the genetic association study based on
SNPs of a single gene. Meta-analysis of the studies provided
some, although limited, support for an association between
endometriosis and both the PGR-PROGINS polymorphism
and ESR1-PvuII polymorphism [42]. However, another study
in a large family-based sample failed to support any associa-
tion between PGR and endometriosis [61]. In this study, no
significant finding was noted on the study of ERa, ERb, and
PGR relevant to the endometriosis. Recently, an international
collaborative study also failed to support the association be-
tween PGR-PROGIN and endometriosis [62]. Taken together,
our results are in accordance with those of Trabert et al [63].
They used a tagSNP approach to characterize a panel of sex
hormone metabolizing genes in endometriosis. Of all genes
(ESR1, ESR2, PGR, CYP17A1, CYP19A1, HSD17B1,
HSD17B2, CYP1A1, CYP1A2, COMT, and GSTM1) tested,
only CYP19 showed a significant association [63].
Although as many SNPs for each gene as possible have
been analyzed in the present study, some limitations must be
considered when evaluating the results of this study. First,
some estrogen-related genes were not included in our model.
We only chose CYP17A1, CYP19A1, and HSD17B in our
study. Second, the sample size was still small for this study,
and this restricts the statistical power to detect associations at
very stringent levels of significance. Finally, our control group
consisted primarily of asymptomatic volunteers. Without
surgical diagnosis, the control population could contain a
substantial number of women with mild endometriosis.
Considering the high frequency of minimal/mild endometri-
osis in asymptomatic women, some investigations considered
early-stage endometriosis as a physiological process. It ap-
pears logical to investigate the early-stage and advanced stage
diseases separately [64].
On the basis of the most recent studies, a hypothesis for the
pathophysiology of endometriosis was proposed in our insti-
tute [65]. In this model, retrograded menses cause inflamma-
tion in the pelvic cavity and the immune cells, led by
macrophages, producing cytokines (IL-1a) that induce over-
expression of cyclooxygenase (COX)-2 in macrophages and
ectopic endometriotic tissues. Expression of COX-2 leads to
increased production and accumulation of prostanoids, espe-
cially prostaglandin E2 (PGE2), in the peritoneal fluid. A link
between inflammation and estrogen production in endometri-
osis was uncovered in a feedback cycle that favors the over-
expression of key steroidogenic genes (most notablyaromatase), overexpression of COX-2, and continuous local
production of E2 and PGE2 in endometriotic tissue [11,15].
The autonomous positive-feedback loop between PGE2 and
estrogen in the ectopic endometriotic lesion might explain the
importance in the pathogenesis of this disorder [65]. The
present results further substantiate the positive findings on the
aromatase gene, the key factor for the synthesis of estrogen,
and the risk of endometriosis. While some enzymes involved
in estrogen metabolism may play no role in the cell growth of
endometriosis due to an altered microenvironment in endo-
metriotic lesions, this study along with previous studies, seems
to suggest that genetic variants of steroid-hormone metabolic
pathways may have only minimal effects on the pathogenesis
of endometriosis [30].Conclusion
Based on this study, we support previously published data
that genetic variation of the CYP19A1 gene may play a sig-
nificant role in this respect. Our data demonstrate an associ-
ation between an SNP of the CYP19A1 gene and
endometriosis, indicating that the CYP19A1 polymorphism is
a candidate genetic susceptibility marker of this disease.
Although previous studies have shown association of ERa,
ERb, PGR, CYP17, HSD17B1, and HSD17B2 with endome-
triosis, these associations could not be replicated in this study.
We also tried to explore the association between HSD17B5
and HSD17B6 with endometriosis, but a negative association
was yielded. This study suggests that genetic variants of
steroid-hormone metabolic pathway genes may have only
minimal effects on the pathogenesis of endometriosis.Acknowledgments
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